/
Metabolic & Endocrine
Insulin Resistance
50
Pipeline Programs↗
24
Active Trials↗
21
Companies Involved↗
Insulin resistance is a moderately active landscape with 50 programs across 21 companies. The most active players are Nanjing Chia-tai Tianqing Pharmaceutical, Boryung Pharmaceutical Co., Ltd. 3 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical35
Phase 19
Phase 23
Phase 33
Approved
No programs
Analysis
Trial Status
186
clinical trials
Completed116 · 62%
Unknown status20 · 11%
Recruiting14 · 8%
Withdrawn13 · 7%
Terminated12 · 6%
Not yet recruiting5 · 3%
Other6 · 3%
Clinical Trials
Trial Activity
186 trials
Investigating the Insulin Resistance in Individuals With Type 2 Diabetes
Recruiting·—·N/A·NCT06428968·30 enrolled
Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance.
Recruiting·—·Phase 1·NCT07224334·30 enrolled
Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy
Recruiting·—·Phase 3·NCT06763328·200 enrolled
Hyperbaric Oxygen Therapy on Insulin Resistance in Postmenopause
Recruiting·—·Phase 1/2·NCT06806345·40 enrolled
Page 1 of 13
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)